Trial Profile
Bortezomib weekly or biweekly as first-line treatment for systemic AL amyloidosis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2014
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Therapeutic Use
- Acronyms ALChemy
- 05 Sep 2014 New trial record